Prefilled Syringes Market Summary

The global prefilled syringes market size was estimated at USD 8.03 billion in 2024 and is projected to reach USD 13.54 billion by 2030, growing at a CAGR of 9.2% from 2025 to 2030. The market growth is primarily driven by the rising prevalence of chronic diseases, which has increased the need for convenient and accurate drug delivery systems. Growing adoption of self-injection devices, coupled with continuous technological advancements that enhance product safety and usability, further supports market expansion as healthcare systems increasingly shift toward patient-centric treatment approaches.

Additionally, supportive government regulations, rising demand for biologics and biosimilars, and the growing shift toward home healthcare are augmenting the overall market growth. Prefilled syringes offer advantages such as reduced risk of dosing errors, improved sterility, and enhanced patient compliance, making them highly preferred for a wide range of therapeutic applications. However, stringent regulatory requirements associated with product approval and the availability of cheaper drug delivery alternatives pose challenges to the market, potentially slowing adoption in certain regions.

Key Market Trends & Insights

• The prefilled syringes industry in Europe dominated the overall global market, supported by advanced healthcare infrastructure, increasing uptake of biologic therapies, and strong presence of key pharmaceutical manufacturers.
• The prefilled syringes industry in the U.S. held a significant share of the North America market in 2024, driven by high demand for chronic disease management solutions and growing acceptance of self-administration in homecare settings.
• By type, the disposable segment accounted for the largest market share of 95.5% in 2024 and is expected to show the fastest CAGR over the forecast period due to its safety benefits and widespread use in routine medical procedures.
• By material, the glass segment accounted for the largest market share of 71.21% in 2024, reflecting the material’s high compatibility with biologics and its long-standing reliability in pharmaceutical packaging.
• By application, the vaccines and immunizations segment accounted for the largest market share of 29.77% in 2024, driven by global immunization programs and increasing awareness of preventive healthcare.

Order a free sample PDF of the Prefilled Syringes Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 8.03 Billion
• 2030 Projected Market Size: USD 13.54 Billion
• CAGR (2025-2030): 9.2%
• Europe: Largest market in 2024

Key Companies & Market Share Insights

The competitive scenario in the prefilled syringes market is highly competitive, with key players such as West Pharmaceuticals; Stevanato Group; and SCHOTT Pharma AG holding significant positions. The major companies are undertaking several organic as well as inorganic strategies such as new product development, regional expansion, acquisitions, mergers, and collaborations for serving the unmet needs of their customers.

Key Players

• BD
• Gerresheimer AG
• SCHOTT Pharma AG
• Stevanato Group
• Nipro Corporation
• Terumo
• West pharmaceuticals
• Fresenius
• Catalent
• Aptar Pharma

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The prefilled syringes market is poised for strong growth as healthcare systems emphasize patient convenience, safety, and efficiency in drug delivery. Rising chronic disease prevalence, increased biologics usage, and expanding home healthcare practices are supporting widespread adoption of prefilled syringe formats. Europe continues to lead the global market thanks to its robust pharmaceutical landscape, while the U.S. also maintains a significant presence. Disposable and glass-based syringes remain dominant due to their superior performance and compatibility. Despite regulatory challenges, growing demand for vaccines, self-injection devices, and advanced therapeutic options will continue to drive market expansion through 2030.